All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
• Esperance Pharmaceuticals Inc., of Baton Rouge, La., began enrolling patients in a randomized, multicenter Phase II trial of EP-100 plus paclitaxel in advanced ovarian cancer. EP-100 is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone-releasing hormone receptors on their surfaces.